Stockreport

Quince Therapeutics Presents Safety Data from Prior Phase 3 ATTeST Clinical Trial at 53rd Child Neurology Society Annual Meeting

Quince Therapeutics, Inc.  (QNCX) 
PDF SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a pati [Read more]